Introduction. A comprehensive study aimed at the search for promising antioxidants and antihypoxants among 1,2,4-triazole-3-thione derivatives for the pharmacological correction of pathological conditions arising as a result of combat actions. The objective was to combine modern methods of computer-based prediction of toxicity and ADME parameters with experimental evaluation of antihypoxic activity in order to determine the most effective and safe candidate compounds for further preclinical and clinical trials. Materials and Methods. The objects of the study were 11 previously synthesized derivatives of 5-(2,4-, 3,4-dimethoxyphenyl)-3H-1,2,4-triazole-3-thiones [19], for which at the in silico stage acute toxicity (LD₅₀, after oral administration to rats) was predicted using TEST 5.1.2.0 software [21], as well as indices of antioxidant activity were determined [14, 19]. For the discussed series of compounds, pharmacotechnological and pharmacokinetic characteristics (solubility, bioavailability, blood–brain barrier permeability, interaction with CYP isoenzymes) were assessed using SwissADME [22]. The experimental part included the study of antihypoxic action in the model of hypoxia with hypercapnia in a closed space on white Wistar rats [23]. Animals received the tested substances at a dose of 100 mg/kg (1/10 of the predicted LD₅₀ value); armadin was used as the reference drug [24]. Results. Analysis of predictive data on acute toxicity indices showed that all studied compounds belong to toxicity classes III–IV according to the OECD classification [21], i.e., they are moderately toxic or low-toxic; thus, no highly toxic samples were identified among them. ADME analysis revealed the most optimal profile in compounds 4–7 (Table 2), which did not inhibit the main CYP450 isoenzymes and demonstrated acceptable solubility and polarity parameters. Experimental evaluation of antihypoxic activity showed that all studied substances (1–11, Table 3) prolonged the survival of animals under the experimental model, with three of them (compounds 3, 7, 8) exceeding the effectiveness of the comparison standard, the widely used drug armadin. Compound 3 prolonged life span by 51.6% relative to control, compound 7 – by 57.9%, derivative 8 – by 55.5%. At the same time, compound 3, namely 4-((5-(3,4-dimethoxyphenyl)-3H-1,2,4-triazol-3-yl)thio)butanonitrile, combined high activity with low toxicity and balanced pharmacotechnological and pharmacokinetic properties, which makes it the most promising for further studies. Conclusions. The synthesized derivatives of 1,2,4-triazole-3-thiones exhibit pronounced antioxidant and antihypoxic activity in combination with an acceptable safety profile. The most promising was defined as 4-((5-(3,4-dimethoxyphenyl)-3H-1,2,4-triazol-3-yl)thio)butanonitrile, which demonstrated an optimal “efficacy/safety” ratio, while compounds 7 and 8, although exceeding the effectiveness of armadin, require additional toxicological and pharmacokinetic analysis. The obtained results confirm the relevance of further preclinical studies of 1,2,4-triazole-3-thione derivatives as potential agents for pharmacological correction of pathological conditions induced by combat actions.